Deucrictibant Data Highlighted in Multiple Presentations at the C1-Inhibitor Deficiency and Angioedema Workshop

ZUG, Switzerland, May 06, 2023 -- Pharvaris , a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema attacks, today announced... | May 6, 2023

Related Keywords

Israel ,Canada ,United States ,Netherlands ,United Kingdom ,Ukraine ,Switzerland ,Hungary ,Russia ,Budapest ,Anna Valerieva ,Remys Peterson ,Anne Lesage ,Henriette Farkas ,Brigitte Loenders ,Marcus Maurer ,Peng Lu ,Marca Riedl ,Globenewswire Inc ,European Union ,Early Development ,Exchange Commission ,Angioedema Workshop ,Chief Medical Officer ,Chief Early Development Officer ,Antagonist Deucrictibant ,Against Bradykinin Effects ,Healthy Volunteers Predicts ,Its Clinical Effects ,Hereditary Angioedema Attacks ,Topline Results ,Mean Symptom Complex Severity ,Treatment Outcome Score ,Statement Regarding Forward Looking ,Annual Report ,Beller Head ,Pharvarisnv Stock Exchange ,News ,Information ,Press Release ,Bay ,023 ,Pharvaris ,Company ,Developing ,Mural ,Antagonists ,O ,Treat ,End ,Prevent ,Hereditary ,Angioedema ,Oday Phvs Nl00150005y4 ,